Biotech: Page 27
-
Getty Images
Regenxbio CEO to step down after 15 years
Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.
By Ned Pagliarulo • June 12, 2024 -
Permission granted by Ultragenyx
Ultragenyx, Mereo drug reduces fractures in bone disorder study
New data show the treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.
By Kristin Jensen • June 12, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.
By BioPharma Dive staff • June 12, 2024 -
Getty Images
Foresite, a biotech venture firm, reloads with $900M fund
Amid some optimism for biotech startups, the firm sees opportunities to fund companies “at all stages of the productive development life cycle,” said managing director Vik Bajaj.
By Gwendolyn Wu • June 12, 2024 -
Getty Images
Ipsen drug for rare liver disease approved by FDA
The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.
By Ned Pagliarulo • June 11, 2024 -
Michael M. Santiago via Getty Images
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
The offering will help fund Phase 3 tests of a drug the biotech claims could be more selective and potent than Bristol’s TYK2 inhibitor.
By Ben Fidler • June 10, 2024 -
Getty Images
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO
After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.
By BioPharma Dive staff • June 7, 2024 -
Warren Little via Getty Images
GSK acquires oligonucleotide drug startup Elsie
The deal, worth up to $50 million, adds to a pipeline GSK is building around nucleic acid drugs, including its hepatitis B candidate bepirovirsen.
By Delilah Alvarado • June 6, 2024 -
Gwendolyn Wu/BioPharma Dive
As biotech recovers, venture firms’ preferences appear to shift
Venture investment into U.S. biotechs is back at pre-COVID levels. But firms seem more selective in the companies they favor, and some are looking toward M&A rather than IPOs for an exit.
By Gwendolyn Wu • Updated June 6, 2024 -
Getty Images
Germany’s ITM raises $205M as radiopharma field booms
The funding will help ITM advance a pipeline that includes a potential competitor to Novartis' neuroendocrine cancer treatment Lutathera.
By Ned Pagliarulo • June 6, 2024 -
Getty Images
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.
By BioPharma Dive staff • June 5, 2024 -
Getty Images
Viking says biopsy data confirm MASH drug’s benefit
The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.
By Jonathan Gardner • June 4, 2024 -
Spencer Platt via Getty Images
Structure pill leads to competitive weight loss in obesity study
Shares in the company soared by more than 50% as study data showed the pill led to similar levels of weight loss as a rival drug being developed by Eli Lilly.
By Delilah Alvarado • June 3, 2024 -
Getty Images
ALS drug developmentEli Lilly adds ALS drug prospect with QurAlis deal
The alliance hands Lilly an RNA-based therapy in preclinical testing for ALS and frontotemporal dementia, and includes a research collaboration to develop other, similar medicines.
By Gwendolyn Wu • June 3, 2024 -
Getty Images
FDA delays decision on Dupixent in COPD; Summit makes a bold claim
Regeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over Keytruda and Neurocrine’s longtime CEO revealed plans to step down.
By BioPharma Dive staff • May 31, 2024 -
Getty Images
Immunovant changes up plans for closely watched autoimmune drugs
The company is prioritizing development of an earlier so-called FcRn inhibitor, a type of medicine that’s shown promise treating multiple inflammatory conditions.
By Kristin Jensen • May 30, 2024 -
Getty Images
CinCor’s ‘hub-and-spoke’ parent nabs new funding to build its next biotechs
The $73 million round for CinRx Pharma, which created a startup AstraZeneca bought last year, will help fund subsidiaries making drugs for obesity, irritable bowel syndrome and gastroparesis.
By Gwendolyn Wu • May 30, 2024 -
Getty Images
A biotech working on a new approach to IVF raises $33M in fresh funding
The Series B funding from Two Sigma Ventures, RA Capital and others will help Gameto develop technology it says could replace hormonal injections and shorten the IVF process.
By Delilah Alvarado • May 29, 2024 -
Getty Images
Merck to buy eye drug developer for $1.3B
An acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.
By Kristin Jensen • May 29, 2024 -
Getty Images
Can robots break the cell therapy bottleneck?
A partnership between cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could address manufacturing hurdles, the CEOs said.
By Michael Gibney • May 29, 2024 -
Elizabeth Regan/BioPharma Dive
Insmed shares double as lung drug data convince Wall Street
After reporting positive clinical trial results for its drug brensocatib, Insmed plans to later this year file for U.S. approval in bronchiectasis that’s not associated with cystic fibrosis.
By Ned Pagliarulo • May 28, 2024 -
Getty Images
Agios cashes in on cancer drug again with $905M Royalty Pharma deal
The deal involves royalties for a brain cancer drug Agios previously sold off and that Royalty Pharma thinks could generate more than $1 billion in U.S. sales.
By Delilah Alvarado • May 28, 2024 -
Getty Images
Roche’s Sabry retires; Duchenne drug fails confirmatory test
The veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative Phase 3 data and Merck unveiled new breast cancer results for Keytruda.
By BioPharma Dive staff • May 28, 2024 -
Getty Images
Orna, a circular RNA specialist, acquires a buzzy startup
After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.
By Jacob Bell • May 23, 2024 -
Michael M. Santiago via Getty Images
Cytokinetics secures up to $575M in royalty deal, frustrating investors
The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said.
By Ned Pagliarulo • May 23, 2024
Previous
